95 related articles for article (PubMed ID: 20727868)
21. Discrepancies between commercially available immunoassays in the detection of tumour-derived hCG.
Mitchell H; Seckl MJ
Mol Cell Endocrinol; 2007 Jan; 260-262():310-3. PubMed ID: 17069967
[No Abstract] [Full Text] [Related]
22. The clinical significance of slightly elevated serum human chorionic gonadotropin levels.
Bar-Hava I; Orvieto R; Homburg R; Dicker D; Ben-Rafael Z
Int J Fertil Menopausal Stud; 1994; 39(6):320-3. PubMed ID: 7889084
[TBL] [Abstract][Full Text] [Related]
23. Studies of monoclonal antibodies against human chorionic gonadotropin. II. Applications of human chorionic gonadotropin monoclonal antibodies on immunoassays.
Chow SN; Hsieh CY; Ouyang PC; Leung WY; Ho-Yuen B; Lee CY
Diagn Immunol; 1986; 4(4):194-200. PubMed ID: 3530599
[TBL] [Abstract][Full Text] [Related]
24. Point-of-care assays for hemoglobin A(1c): is performance adequate?
Little RR; Lenters-Westra E; Rohlfing CL; Slingerland R
Clin Chem; 2011 Sep; 57(9):1333-4. PubMed ID: 21712548
[No Abstract] [Full Text] [Related]
25. Evaluation of a training program for device operators in the Australian Government's Point of Care Testing in General Practice Trial: issues and implications for rural and remote practices.
Shephard MD; Mazzachi BC; Watkinson L; Shephard AK; Laurence C; Gialamas A; Bubner T
Rural Remote Health; 2009; 9(3):1189. PubMed ID: 19689171
[TBL] [Abstract][Full Text] [Related]
26. Clinical governance: implications for point-of-care testing.
Freedman DB
Ann Clin Biochem; 2002 Sep; 39(Pt 5):421-3. PubMed ID: 12227847
[TBL] [Abstract][Full Text] [Related]
27. Beyond traditional quality control. How to check costs and quality of point-of-care testing.
Hortin GL
MLO Med Lab Obs; 1997 Sep; 29(9):31-2, 34, 36-7. PubMed ID: 10174098
[No Abstract] [Full Text] [Related]
28. Quality assessment in point-of-care coagulation testing.
Kitchen DP; Kitchen S; Jennings I; Woods T; Walker I
Semin Thromb Hemost; 2008 Oct; 34(7):647-53. PubMed ID: 19085765
[TBL] [Abstract][Full Text] [Related]
29. ICSH Guideline for worldwide point-of-care testing in haematology with special reference to the complete blood count.
Briggs C; Carter J; Lee SH; Sandhaus L; Simon-Lopez R; Vives Corrons JL;
Int J Lab Hematol; 2008 Apr; 30(2):105-16. PubMed ID: 18333842
[TBL] [Abstract][Full Text] [Related]
30. Factors affecting QuickVue Influenza A + B rapid test performance in the community setting.
Cheng CK; Cowling BJ; Chan KH; Fang VJ; Seto WH; Yung R; Uyeki TM; Houck PM; Peiris JS; Leung GM
Diagn Microbiol Infect Dis; 2009 Sep; 65(1):35-41. PubMed ID: 19679233
[TBL] [Abstract][Full Text] [Related]
31. [Utility and directions of POCT (point of care testing) in diagnosis of infectious disease].
Shimetani N
Nihon Rinsho; 2010 Jun; 68 Suppl 6():130-4. PubMed ID: 20942020
[No Abstract] [Full Text] [Related]
32. Alarmingly poor performance in Chlamydia trachomatis point-of-care testing.
van Dommelen L; van Tiel FH; Ouburg S; Brouwers EE; Terporten PH; Savelkoul PH; Morré SA; Bruggeman CA; Hoebe CJ
Sex Transm Infect; 2010 Oct; 86(5):355-9. PubMed ID: 20876754
[TBL] [Abstract][Full Text] [Related]
33. Immulite 2000 LH assay: manufacturer's reply.
Faye S
Ann Clin Biochem; 2002 Jul; 39(Pt 4):417. PubMed ID: 12150163
[No Abstract] [Full Text] [Related]
34. External quality assessment for prothrombin time/international normalised ratio using point-of-care devices: split-sample or conventional external quality assessment using control samples?
Kitchen D; Murray E; Kitchen S; Jennings I; Fitzmaurice D; Woods T; Walker I
Scand J Clin Lab Invest; 2007; 67(7):673-5; author reply 676-7. PubMed ID: 17963156
[No Abstract] [Full Text] [Related]
35. Assessing the risk of false negative point-of-care urinary human chorionic gonadotropin device results due to beta core fragment.
Gronowski AM; Nerenz RD
Clin Biochem; 2015 Feb; 48(3):97-8. PubMed ID: 25578769
[No Abstract] [Full Text] [Related]
36. Assessment of biotin interference with qualitative point-of-care hCG test devices.
Williams GR; Cervinski MA; Nerenz RD
Clin Biochem; 2018 Mar; 53():168-170. PubMed ID: 29395091
[TBL] [Abstract][Full Text] [Related]
37. Ambulatory human chorionic gonadotrophin (hCG) testing: a verification of two hCG point of care devices.
Kyriacou C; Yang W; Kapur S; Maheetharan S; Pikovsky M; Parker N; Barcroft J; Bobdiwala S; Sur S; Stalder C; Gould D; Ofili-Yebovi D; Day A; Unsworth N; Wilkes EH; Tan T; Bourne T
Clin Chem Lab Med; 2024 Mar; 62(4):664-673. PubMed ID: 37886834
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of 2 commercial methods for the determination of beta HCG (radioimmunoassay versus immunoenzyme assay)].
Forsbach G; Vargas E; Motta M; Joffre G; De Hoyos R
Ginecol Obstet Mex; 1986 Nov; 54():294-6. PubMed ID: 2434390
[No Abstract] [Full Text] [Related]
39. The need for a point of care testing: an evidence-based appraisal.
Collinson PO
Scand J Clin Lab Invest Suppl; 1999; 230():67-73. PubMed ID: 10389204
[TBL] [Abstract][Full Text] [Related]
40. Quality control of CoaguChek test strips in the Netherlands.
van den Besselaar AM; Hoekstra MM; van der Meer FJ
Thromb Haemost; 2007 Feb; 97(2):323-4. PubMed ID: 17264967
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
